The U.S. Food and Drug Administration (FDA) has rejected an application from Disc Medicine seeking accelerated approval of its experimental oral therapy bitopertin as a treatment for erythropoietic protoporphyria (EPP). According to Disc, the FDA said available clinical data aren’t sufficient to conclude that bitopertin is likely to…